Literature DB >> 9399209

Symptoms and duration of the prodromal phase in Parkinson's disease.

E G Gonera1, M van't Hof, H J Berger, C van Weel, M W Horstink.   

Abstract

To investigate the duration of a prodromal phase before the onset of the classic symptoms of idiopathic Parkinson's disease, the authors conducted a retrospective case-control study of 60 patients with Parkinson's disease and 58 age- and sex-matched control subjects, covering the decade preceding the onset of classic Parkinson's disease. The symptoms were derived from files of the patients' general practitioners. Compared with control subjects, patients pre-Parkinson's disease had more central nervous system, psychologic, musculoskeletal, and cardiovascular (i.e., autonomic) symptoms. Patients pre-Parkinson's disease also made more visits to general practitioners and medical specialists. The results indicate that the onset of classic parkinsonism is frequently preceded by a prodromal phase lasting from 4-6 years.

Entities:  

Mesh:

Year:  1997        PMID: 9399209     DOI: 10.1002/mds.870120607

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  46 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  D Aarsland; K Karlsen
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

3.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

4.  Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.

Authors:  Hua Wang; Anzari Atik; Tessandra Stewart; Carmen Ginghina; Patrick Aro; Kathleen F Kerr; John Seibyl; Danna Jennings; Poul Henning Jensen; Kenneth Marek; Min Shi; Jing Zhang
Journal:  Neurobiol Dis       Date:  2018-04-27       Impact factor: 5.996

Review 5.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 6.  The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.

Authors:  Lena F Burbulla; Dimitri Krainc
Journal:  Neurobiol Dis       Date:  2019-07-25       Impact factor: 5.996

7.  Occurrence of depression and anxiety prior to Parkinson's disease.

Authors:  E L Jacob; N M Gatto; A Thompson; Y Bordelon; B Ritz
Journal:  Parkinsonism Relat Disord       Date:  2010-08-01       Impact factor: 4.891

8.  Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Authors:  Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

9.  Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine.

Authors:  Katsuaki Suzuki; Kyoko Okada; Tomoyasu Wakuda; Chie Shinmura; Yosuke Kameno; Keiko Iwata; Taro Takahashi; Shiro Suda; Hideo Matsuzaki; Yasuhide Iwata; Kenji Hashimoto; Norio Mori
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

10.  Parkinson's disease: is it a toxic syndrome?

Authors:  Seham A Gad Elhak; Abdel Aziz A Ghanem; Hassan Abdelghaffar; Sahar El Dakroury; Mohamed M Salama
Journal:  Neurol Res Int       Date:  2010-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.